| Dr Victor Allon Mcpherson, MD, MSC | |
|
1275 York Ave, New York, NY 10065-6007 | |
| (551) 444-8672 | |
| Not Available |
| Full Name | Dr Victor Allon Mcpherson |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 1275 York Ave, New York, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013411867 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | P05550 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Victor Allon Mcpherson, MD, MSC 1233 York Ave Apt 21i, New York, NY 10065-6342 Ph: (551) 444-8672 | Dr Victor Allon Mcpherson, MD, MSC 1275 York Ave, New York, NY 10065-6007 Ph: (551) 444-8672 |
News Archive
The call to eliminate all funding for HIV/AIDS vaccine research and prevention programs and "shifting" those funds to the expansion of HIV/AIDS treatment is a "dangerous sentiment" that is "sweeping over the AIDS establishment," Laurie Garrett, a senior fellow for global health at the Council on Foreign Relations, writes in an International Herald Tribune opinion piece.
Watson Pharmaceuticals, Inc., a leading specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc., has been sued by Endo Pharmaceuticals Inc. and Penwest Pharmaceuticals Co. in connection with the filing of Watson's Abbreviated New Drug Application (ANDA) for Oxymorphone Hydrochloride Extended-Release Tablets, 40mg.
PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.
Of high-risk therapeutic devices approved via the Food and Drug Administration Premarket Approval (PMA) pathway between 2010 and 2011, there has been wide variation in both the number and quality of premarket and postmarket studies, with approximately 13 percent of initiated postmarket studies completed between 3 and 5 years after FDA approval, according to a study in the August 11 issue of JAMA.
› Verified 1 days ago
Dr. Reza Mehrazin, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Gustave L Levy Pl # 1272, Mount Sinai School Of Medicine / Urology Dept, New York, NY 10029 Phone: 212-241-4812 Fax: 212-987-4675 | |
Dr. Joseph Paul Alukal, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 150 E 32nd St, 2nd Floor, New York, NY 10016 Phone: 646-825-6300 Fax: 646-825-6399 | |
Dr. Lamont Jordan Barlow, Urology Medicare: Medicare Enrolled Practice Location: 423 E 23rd St, New York, NY 10010 Phone: 212-686-7500 | |
Matthew Katz, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 222 E 41st St, New York, NY 10017 Phone: 646-825-6300 | |
Mark Thomas Dawidek, Urology Medicare: Not Enrolled in Medicare Practice Location: 303 E 60th St Apt 32g, New York, NY 10022 Phone: 236-989-9955 | |
David M Weiner, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 161 Fort Washington Ave, 11th Floor, New York, NY 10032 Phone: 212-305-0114 Fax: 212-305-0129 |